drugset
drugset / Trial / NCT06079372

Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa

NCT06079372 ↗

Phase 3 Active not recruiting 43 enrolled Alexion Pharmaceuticals, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary purpose of this study is to assess the safety and tolerability of ALXN1850 versus asfotase alfa in pediatric participants with HPP previously treated with asfotase alfa.

Timeline

Start
2024-04-02
Primary completion
2025-07-23
Completion
2028-02-29

Drugs

EvaluationDrugModalityDoseRoute
Subject asfotase alfa Protein / enzyme biologic 1 mg/kg Subcutaneous
Subject asfotase alfa Protein / enzyme biologic 2 mg/kg Subcutaneous
Subject efzimfotase alfa Protein / enzyme biologic 20 mg Subcutaneous
Subject efzimfotase alfa Protein / enzyme biologic 35 mg Subcutaneous
Subject efzimfotase alfa Protein / enzyme biologic 50 mg Subcutaneous

Indications

hypophosphatasia